These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 24497635

  • 1. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.
    Mustaev A, Malik M, Zhao X, Kurepina N, Luan G, Oppegard LM, Hiasa H, Marks KR, Kerns RJ, Berger JM, Drlica K.
    J Biol Chem; 2014 May 02; 289(18):12300-12. PubMed ID: 24497635
    [Abstract] [Full Text] [Related]

  • 2. Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design.
    Drlica K, Mustaev A, Towle TR, Luan G, Kerns RJ, Berger JM.
    ACS Chem Biol; 2014 Dec 19; 9(12):2895-904. PubMed ID: 25310082
    [Abstract] [Full Text] [Related]

  • 3. The C7-aminomethylpyrrolidine group rescues the activity of a thio-fluoroquinolone.
    Lentz SRC, Chheda PR, Oppegard LM, Towle TR, Kerns RJ, Hiasa H.
    Biochimie; 2019 May 19; 160():24-27. PubMed ID: 30763638
    [Abstract] [Full Text] [Related]

  • 4. Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones.
    Malik M, Mustaev A, Schwanz HA, Luan G, Shah N, Oppegard LM, de Souza EC, Hiasa H, Zhao X, Kerns RJ, Drlica K.
    Nucleic Acids Res; 2016 Apr 20; 44(7):3304-16. PubMed ID: 26984528
    [Abstract] [Full Text] [Related]

  • 5. Dual Escherichia coli DNA Gyrase A and B Inhibitors with Antibacterial Activity.
    Fois B, Skok Ž, Tomašič T, Ilaš J, Zidar N, Zega A, Peterlin Mašič L, Szili P, Draskovits G, Nyerges Á, Pál C, Kikelj D.
    ChemMedChem; 2020 Feb 05; 15(3):265-269. PubMed ID: 31721445
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
    Kern G, Palmer T, Ehmann DE, Shapiro AB, Andrews B, Basarab GS, Doig P, Fan J, Gao N, Mills SD, Mueller J, Sriram S, Thresher J, Walkup GK.
    J Biol Chem; 2015 Aug 21; 290(34):20984-20994. PubMed ID: 26149691
    [Abstract] [Full Text] [Related]

  • 7. Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.
    Chan PF, Srikannathasan V, Huang J, Cui H, Fosberry AP, Gu M, Hann MM, Hibbs M, Homes P, Ingraham K, Pizzollo J, Shen C, Shillings AJ, Spitzfaden CE, Tanner R, Theobald AJ, Stavenger RA, Bax BD, Gwynn MN.
    Nat Commun; 2015 Dec 07; 6():10048. PubMed ID: 26640131
    [Abstract] [Full Text] [Related]

  • 8. gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.
    Heddle JG, Lu T, Zhao X, Drlica K, Maxwell A.
    J Mol Biol; 2001 Jun 22; 309(5):1219-31. PubMed ID: 11399091
    [Abstract] [Full Text] [Related]

  • 9. Functional Characterization of the DNA Gyrases in Fluoroquinolone-Resistant Mutants of Francisella novicida.
    Caspar Y, Siebert C, Sutera V, Villers C, Aubry A, Mayer C, Maurin M, Renesto P.
    Antimicrob Agents Chemother; 2017 Apr 22; 61(4):. PubMed ID: 28167561
    [Abstract] [Full Text] [Related]

  • 10. Impact of mutations in DNA gyrase genes on quinolone resistance in Campylobacter jejuni.
    Changkwanyeun R, Yamaguchi T, Kongsoi S, Changkaew K, Yokoyama K, Kim H, Suthienkul O, Usui M, Tamura Y, Nakajima C, Suzuki Y.
    Drug Test Anal; 2016 Oct 22; 8(10):1071-1076. PubMed ID: 26857529
    [Abstract] [Full Text] [Related]

  • 11. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.
    Lu T, Zhao X, Drlica K.
    Antimicrob Agents Chemother; 1999 Dec 22; 43(12):2969-74. PubMed ID: 10582891
    [Abstract] [Full Text] [Related]

  • 12. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.
    Pantel A, Petrella S, Matrat S, Brossier F, Bastian S, Reitter D, Jarlier V, Mayer C, Aubry A.
    Antimicrob Agents Chemother; 2011 Oct 22; 55(10):4524-9. PubMed ID: 21768507
    [Abstract] [Full Text] [Related]

  • 13. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
    Pan XS, Yague G, Fisher LM.
    Antimicrob Agents Chemother; 2001 Nov 22; 45(11):3140-7. PubMed ID: 11600369
    [Abstract] [Full Text] [Related]

  • 14. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM, Lawrence JM, Josty IC, Hopewell R, Margerrison EE, Cullen ME.
    Am J Med; 1989 Nov 30; 87(5A):2S-8S. PubMed ID: 2574005
    [Abstract] [Full Text] [Related]

  • 15. The pentapeptide repeat proteins MfpAMt and QnrB4 exhibit opposite effects on DNA gyrase catalytic reactions and on the ternary gyrase-DNA-quinolone complex.
    Mérens A, Matrat S, Aubry A, Lascols C, Jarlier V, Soussy CJ, Cavallo JD, Cambau E.
    J Bacteriol; 2009 Mar 30; 191(5):1587-94. PubMed ID: 19060136
    [Abstract] [Full Text] [Related]

  • 16. Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis.
    Malik M, Marks KR, Mustaev A, Zhao X, Chavda K, Kerns RJ, Drlica K.
    Antimicrob Agents Chemother; 2011 May 30; 55(5):2335-43. PubMed ID: 21383100
    [Abstract] [Full Text] [Related]

  • 17. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J, Robicsek A, Hooper DC.
    Antimicrob Agents Chemother; 2006 Feb 30; 50(2):600-6. PubMed ID: 16436716
    [Abstract] [Full Text] [Related]

  • 18. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.
    Aldred KJ, Blower TR, Kerns RJ, Berger JM, Osheroff N.
    Proc Natl Acad Sci U S A; 2016 Feb 16; 113(7):E839-46. PubMed ID: 26792518
    [Abstract] [Full Text] [Related]

  • 19. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.
    Black MT, Stachyra T, Platel D, Girard AM, Claudon M, Bruneau JM, Miossec C.
    Antimicrob Agents Chemother; 2008 Sep 16; 52(9):3339-49. PubMed ID: 18625781
    [Abstract] [Full Text] [Related]

  • 20. Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.
    Zhou Y, Yu L, Li J, Zhang L, Tong Y, Kan B.
    Int J Antimicrob Agents; 2013 Jul 16; 42(1):72-5. PubMed ID: 23643392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.